Crossref
Hemoglobin Switching, Sickle-Cell Therapy, and the Future of Gene Editing
Harvard Undergraduate Health Policy Review · 2026 · 26 (1)
DOI: 10.56927/894668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Harvard Undergraduate Health Policy Review, 2026. Verfasst von Linda Liu.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Liu, L. (2026). Hemoglobin Switching, Sickle-Cell Therapy, and the Future of Gene Editing. Harvard Undergraduate Health Policy Review, 26(1). https://doi.org/10.56927/894668
Vancouver
Liu L. Hemoglobin Switching, Sickle-Cell Therapy, and the Future of Gene Editing. Harvard Undergraduate Health Policy Review. 2026;26(1). doi:10.56927/894668
BibTeX
@article{Liu2026,
author = {Liu, Linda},
title = {Hemoglobin Switching, Sickle-Cell Therapy, and the Future of Gene Editing},
journal = {Harvard Undergraduate Health Policy Review},
year = {2026},
volume = {26},
number = {1},
doi = {10.56927/894668}
}
EUVIMED